CYP2C19 catalyzes the bioactivation of the antiplatelet prodrug clopidogrel, and CYP2C19
genotype impacts clopidogrel active metabolite formation. CYP2C19 intermediate and poor …

Inter-individual variability in drug response, be it efficacy or safety, is common and likely to
become an increasing problem globally given the growing elderly population requiring …

Background Dual antiplatelet treatment has been shown to lower the risk of recurrent stroke
as compared with aspirin alone when treatment is initiated early (≤ 24 hours) after an acute …

The management of patients with stroke is often multidisciplinary, involving various
specialties and healthcare professionals. Given the common shared risk factors for stroke …

Stroke is the second leading cause of death worldwide and a complex, heterogeneous
condition. In this review, we provide an overview of the current knowledge on monogenic …

Background Individuals with ischemic stroke or transient ischemic attack (TIA) have a high
early risk of ischemic stroke despite dual antiplatelet therapy. The risk of ischemic stroke …

Platelets have a crucial role in haemostasis and atherothrombosis. Pharmacological control
of platelet hyper-reactivity has become a cornerstone in the prevention of thrombo …

Background Antiplatelet and antithrombotic medication management before, during, and
after neurointerventional procedures has significant practice variation. This document …

The past decade has seen significant advances in stroke prevention. These advances
include new antithrombotic agents, new options for dyslipidemia treatment, and novel …

Stroke is a devastating condition with significant morbidity and mortality worldwide.
Antithrombotic therapy plays a crucial role in both primary and secondary prevention of …